Standardized classification and reporting of glomerulonephritis.
Sethi S, Fervenza FC.
Nephrol Dial Transplant. 2019 Feb 1;34(2):193-199. doi: 10.1093/ndt/gfy220.
Mesangial proliferative glomerulonephritis in southwestern American Indians.
Hoy WE, Hughson MD, Smith SM, Megill DM.
Am J Kidney Dis. 1993 May;21(5):486-96. doi: 10.1016/s0272-6386(12)80394-5.
Expression and clinical significance of thrombospondin-1 and plasminogen activator inhibitor-1 in patients with mesangial proliferative glomerulonephritis.
Pan C, Zhou C, Shan A, Chen N.
Ann Palliat Med. 2020 Sep;9(5):3187-3193. doi: 10.21037/apm-20-1291. Epub 2020 Aug 31.
Role of interleukin-6 in the progression of mesangial proliferative glomerulonephritis.
Horii Y, Iwano M, Hirata E, Shiiki M, Fujii Y, Dohi K, Ishikawa H.
Kidney Int Suppl. 1993 Jan;39:S71-5.
[Henoch-Shönlein purpura].
Pillebout E, Nochy D, Thervet E.
Nephrol Ther. 2009 Dec;5(7):663-75. doi: 10.1016/j.nephro.2009.02.001. Epub 2009 Apr 2.
Pediatric Mesangial Proliferative Glomerulonephritis Has Increased the Platelet Thrombus Formation Potentials under High-Shear Flow Condition.
Omae T, Ishikawa T, Ogiwara K, Nogami K.
Nephron. 2024;148(6):415-425. doi: 10.1159/000534494. Epub 2023 Oct 9.
Urinary protein markers predict the severity of renal histological lesions in children with mesangial proliferative glomerulonephritis.
Li Y, Wang J, Zhu X, Feng Q, Li X, Feng X.
BMC Nephrol. 2012 May 20;13:29. doi: 10.1186/1471-2369-13-29.
The role of the mesangial cell in proliferative glomerulonephritis.
Davison AM, Thomson D, MacDonald MK, Uttley WS, Robson JS.
J Clin Pathol. 1973 Mar;26(3):198-208. doi: 10.1136/jcp.26.3.198.
Urinary neopterin: an immune activation marker in mesangial proliferative glomerulonephritis.
Ueno K, Shimizu M, Yokoyama T, Ishikawa S, Tasaki Y, Inoue N, Sugimoto N, Ohta K, Yachie A.
Clin Exp Nephrol. 2015 Apr;19(2):264-70. doi: 10.1007/s10157-014-0984-z. Epub 2014 May 25.
Overlap of Thrombotic Microangiopathy and Mesangial Proliferative Glomerulonephritis Caused by Combination Therapy with Atezolizumab and Bevacizumab.
Horino T, Eguchi T, Inotani S, Hirose A, Ishihara M, Yagyu K, Uchida K, Fujieda M, Terada Y.
Intern Med. 2023 Jan 1;62(1):91-94. doi: 10.2169/internalmedicine.9425-22. Epub 2022 Jun 14.
